Immunotherapy duo takes on bile duct cancer in new trial
NCT ID NCT07369791
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This Phase II trial tests whether adding two immunotherapy drugs (nivolumab and relatlimab) to standard chemotherapy can shrink tumors better than chemotherapy plus just one immunotherapy drug in people with advanced biliary tract cancer. The study will enroll 76 adults whose cancer has spread or cannot be removed by surgery and who have not had prior treatment for advanced disease. The main goal is to see how many patients have their tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab and relatlimab (immunotherapy drugs) plus gemcitabine and cisplatin (chemotherapy)
- What this could lead to
- If successful, this could offer a new first-line treatment option that improves tumor shrinkage rates for people with advanced biliary tract cancer.
- What could go wrong
- This is a small, early Phase II trial with only 76 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER(BTC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taipei Veterans General Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.